EAM
AXSM icon

Eventide Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Eventide Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.5M Sell
316,820
-202,738
-39% -$44M 1.04% 27
2026
Q1 		$87.8M Sell
519,558
-51,668
-9% -$8.92M 1.45% 14
2025
Q4 		$104M Sell
571,226
-175,172
-23% -$24.5M 1.63% 10
2025
Q3 		$90.6M Buy
746,398
+20,726
+3% +$2.33M 1.49% 14
2025
Q2 		$75.7M Sell
725,672
-19,178
-3% -$2.03M 1.33% 17
2025
Q1 		$86.9M Sell
744,850
-83,861
-10% -$9.55M 1.73% 9
2024
Q4 		$70.1M Buy
828,711
+824
+0.1% +$75.8K 1.28% 23
2024
Q3 		$74.4M Sell
827,887
-110,827
-12% -$9.67M 1.28% 22
2024
Q2 		$75.6M Buy
938,714
+592,002
+171% +$43.8M 1.29% 23
2024
Q1 		$27.7M Hold
346,712
– – 0.43% 71
2023
Q4 		$27.6M Hold
346,712
– – 0.45% 67
2023
Q3 		$24.2M Buy
+346,712
New +$25.9M 0.44% 68

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eventide Asset Management's AXSM Position: Q2 2026 in Review

Eventide Asset Management reduced its Axsome Therapeutics (AXSM) stake by 39% in Q2 2026, selling an estimated $44M and leaving 316,820 shares worth $77.5M. The position accounts for 1.04% of the portfolio, ranked #27.

Eventide Asset Management first reported a position in AXSM in Q3 2023 and has held it in 12 quarters since. The position peaked at $104M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Eventide Asset Management held 316,820 shares of Axsome Therapeutics worth $77.5M as of Q2 2026.
  • Eventide Asset Management sold 202,738 Axsome Therapeutics shares in Q2 2026, an estimated $44M.
  • Axsome Therapeutics made up 1.04% of Eventide Asset Management's portfolio in Q2 2026, its #27 holding.
  • Eventide Asset Management first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Eventide Asset Management's Axsome Therapeutics position peaked at $104M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.